Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Asieris Starts China Phase III Trial of Bladder Cancer Diagnostic

publication date: Nov 7, 2022

Shanghai Asieris Pharma dosed the first patient in a China Phase III of Hexvix®, a contrast product used to diagnose bladder cancer. Asieris acquired China-Taiwan rights to the candidate from Oslo’s Photocure ASA in early 2021. Hexvix is used for cystoscopic detection of bladder cancer, including papillary tumors and carcinoma in situ (CIS). When used with BLC®, the fluorescence from tumor tissue appears bright pink, while normal tissue remains dark blue. Asieris focuses on developing innovative drugs for genitourinary tumors and related diseases. More details....

Stock Symbol: (SHA: 688176)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital